CRSP
Price
$49.59
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
41 days until earnings call
SPRO
Price
$1.34
Change
-$0.00 (-0.00%)
Updated
Sep 18 closing price
48 days until earnings call
Ad is loading...

CRSP vs SPRO

Header iconCRSP vs SPRO Comparison
Open Charts CRSP vs SPROBanner chart's image
CRISPR Therapeutics AG
Price$49.59
Change-$0.00 (-0.00%)
Volume$1.69M
CapitalizationN/A
Spero Therapeutics
Price$1.34
Change-$0.00 (-0.00%)
Volume$119.81K
CapitalizationN/A
View a ticker or compare two or three
CRSP vs SPRO Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CRSP vs. SPRO commentary
Sep 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and SPRO is a Hold.

COMPARISON
Comparison
Sep 19, 2024
Stock price -- (CRSP: $49.55 vs. SPRO: $1.34)
Brand notoriety: CRSP and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 128% vs. SPRO: 90%
Market capitalization -- CRSP: $4.25B vs. SPRO: $72.43M
CRSP [@Biotechnology] is valued at $4.25B. SPRO’s [@Biotechnology] market capitalization is $72.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $599.73B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while SPRO’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 4 bearish.
  • SPRO’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than SPRO.

Price Growth

CRSP (@Biotechnology) experienced а +9.04% price change this week, while SPRO (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.38%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1.46%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 30, 2024.

SPRO is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+7.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.25B) has a higher market cap than SPRO($72.4M). SPRO YTD gains are higher at: -8.844 vs. CRSP (-20.847). SPRO has higher annual earnings (EBITDA): 19.6M vs. CRSP (-335.17M). CRSP has more cash in the bank: 484M vs. SPRO (63.5M). SPRO has less debt than CRSP: SPRO (4.94M) vs CRSP (231M). CRSP has higher revenues than SPRO: CRSP (200M) vs SPRO (105M).
CRSPSPROCRSP / SPRO
Capitalization4.25B72.4M5,866%
EBITDA-335.17M19.6M-1,710%
Gain YTD-20.847-8.844236%
P/E RatioN/A3.94-
Revenue200M105M190%
Total Cash484M63.5M762%
Total Debt231M4.94M4,678%
FUNDAMENTALS RATINGS
CRSP vs SPRO: Fundamental Ratings
CRSP
SPRO
OUTLOOK RATING
1..100
1371
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
96100
SMR RATING
1..100
9438
PRICE GROWTH RATING
1..100
6252
P/E GROWTH RATING
1..100
8292
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (63) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's Profit vs Risk Rating (96) in the Biotechnology industry is in the same range as SPRO (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to SPRO’s over the last 12 months.

SPRO's SMR Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (94) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CRSP’s over the last 12 months.

SPRO's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as CRSP (62) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (82) in the Biotechnology industry is in the same range as SPRO (92) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to SPRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPSPRO
RSI
ODDS (%)
Bullish Trend 7 days ago
66%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 7 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 16 days ago
85%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FBK47.950.61
+1.29%
FB Financial Corp
UI207.650.49
+0.24%
Ubiquiti
DHR271.90-0.57
-0.21%
Danaher Corp
NVTS2.28-0.03
-1.30%
Navitas Semiconductor Corp
DTIL9.60-0.62
-6.07%
Precision BioSciences

SPRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRO has been loosely correlated with LXRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRO jumps, then LXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRO
1D Price
Change %
SPRO100%
+0.75%
LXRX - SPRO
41%
Loosely correlated
+1.23%
CRSP - SPRO
36%
Loosely correlated
-0.64%
DNLI - SPRO
36%
Loosely correlated
+0.26%
BEAM - SPRO
35%
Loosely correlated
-0.27%
XNCR - SPRO
35%
Loosely correlated
-0.81%
More